A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-07

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be a single-center, randomized, parallel, open-label, single dosing bridging study in healthy subjects to evaluate the pharmacokinetics and safety of two formulations of SHR-1314.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment

NCT03160014

Hepatic Impairment

UNKNOWN PHASE1

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

NCT04631549

Hepatic Impairment Healthy Participants

UNKNOWN PHASE1

Pharmacokinetics of HR17031 Injection in Healthy Subjects

NCT05031871

Type 2 Diabetes Mellitus

COMPLETED PHASE1

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

NCT04305392

Hepatic Impairment

UNKNOWN PHASE1

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

NCT05370950

Hypercholesterolemia and Hyperlipidemia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a single-center, randomized, parallel, open-label, single dosing (SHR-1314 240mg) bridging study in healthy subjects to evaluate the pharmacokinetics and safety of two formulations of SHR-1314.

The study will consist of a 14-days screening period (-14\~-1 days); an observation period (1-3 days) and the follow-up period (4-113 days); Subjects will be randomly assigned to three group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pharmacokinetic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SHR-1314 A

single dosing SHR-1314 A

Group Type EXPERIMENTAL

SHR-1314

Intervention Type DRUG

single dosing

SHR-1314 B

single dosing SHR-1314 B

Group Type EXPERIMENTAL

SHR-1314

Intervention Type DRUG

single dosing

SHR-1314 C

single dosing SHR-1314 C

Group Type EXPERIMENTAL

SHR-1314

Intervention Type DRUG

single dosing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SHR-1314

single dosing

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent must be obtained before any assessment is performed.Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations.
* Men or women at least 18 years and no more than 45 years of age at time of screening.
* Men with a body weight ≥50 kg or women with a body weight ≥45kg, with BMI range from 18 to 25.
* Subjects with normal physical examination results and with normal laboratory results (blood, chemistry, urine, drug screening, coagulation function test), ECG and X-ray chest test are normal or with certain abnormal without clinical significance.

Exclusion Criteria

* Presence of significant medical problems, with investigator's judge that not proper to participate clinical study
* History of hypersensitivity to any of study drug constituent
* History or current infection with human immunodeficiency virus (HIV) or hepatitis C; or current hepatitis B infection or syphilis
* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years
* History of chronic or recurrent infectious disease, or evidence of active or latent tuberculosis infection.
* Those who have participated in any clinical study for any drug or medical device within 3 months before screening
* Those who have been vaccinated with live attenuated vaccine within 12 weeks prior to screening
* History or evidence of ongoing alcohol or drug abuse, within the last six months before Baseline.
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
* Subjects judged by the investigator as unsuitable for participating in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes